MedTrace Logo

Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)

NCT06427447 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 770

Last updated 2025-02-04

No results posted yet for this study

Summary

In this trial, we aim to compare the outcomes of adjuvant chemoradiotherapy with chemotherapy for patients with resected pancreatic cancer who are at high risk of disease progressions.

Conditions

Interventions

COMBINATION_PRODUCT

Adjuvant chemoradiotherapy

Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)

DRUG

Adjuvant chemotherapy

Chemotherapy (gemcitabine plus capecitabine)

Sponsors & Collaborators

  • Changhai Hospital

    lead OTHER

Principal Investigators

  • Huojun Zhang, M.D. · Changhai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-06
Primary Completion
2028-06-30
Completion
2029-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06427447 on ClinicalTrials.gov